Oral Immune-Related Adverse Events Following Durvalumab Administration

Dulyapong Rungraungrayabkul; Nis Okuma

doi:10.1111/odi.70057

Oral Immune-Related Adverse Events Following Durvalumab Administration

Department of Oral Medicine and Periodontology

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	1184-1186
Number of pages	3
Journal	Oral Diseases
Volume	32
Issue number	4
DOIs	https://doi.org/10.1111/odi.70057
Publication status	Published - Apr 2026

Keywords

PD-1 inhibitor
durvalumab
immune-related adverse events
oral lichen planus
oral lichenoid lesion

Access to Document

10.1111/odi.70057

Cite this

@article{e446134eac6f4d029f97ef7894db5e51,

title = "Oral Immune-Related Adverse Events Following Durvalumab Administration",

keywords = "PD-1 inhibitor, durvalumab, immune-related adverse events, oral lichen planus, oral lichenoid lesion",

author = "Dulyapong Rungraungrayabkul and Nis Okuma",

year = "2026",

month = apr,

doi = "10.1111/odi.70057",

language = "English",

volume = "32",

pages = "1184--1186",

journal = "Oral Diseases",

issn = "1354-523X",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Oral Immune-Related Adverse Events Following Durvalumab Administration

AU - Rungraungrayabkul, Dulyapong

AU - Okuma, Nis

PY - 2026/4

Y1 - 2026/4

KW - PD-1 inhibitor

KW - durvalumab

KW - immune-related adverse events

KW - oral lichen planus

KW - oral lichenoid lesion

UR - https://www.scopus.com/pages/publications/105012458201

U2 - 10.1111/odi.70057

DO - 10.1111/odi.70057

M3 - Letter

AN - SCOPUS:105012458201

SN - 1354-523X

VL - 32

SP - 1184

EP - 1186

JO - Oral Diseases

JF - Oral Diseases

IS - 4

ER -

Oral Immune-Related Adverse Events Following Durvalumab Administration

Keywords

Access to Document

Other files and links

Cite this